Claritev (NYSE:CTEV – Get Free Report) CEO Travis Dalton bought 5,110 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average price of $29.34 per share, for a total transaction of $149,927.40. Following the acquisition, the chief executive officer owned 57,432 shares in the company, valued at approximately $1,685,054.88. This represents a 9.77% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Travis Dalton also recently made the following trade(s):
- On Thursday, August 27th, Travis Dalton acquired 4,500 shares of Claritev stock. The stock was acquired at an average price of $38.81 per share, for a total transaction of $174,645.00.
- On Friday, August 28th, Travis Dalton bought 1,950 shares of Claritev stock. The shares were acquired at an average cost of $38.48 per share, with a total value of $75,036.00.
Claritev Stock Up 0.3%
CTEV stock opened at $26.89 on Monday. The business has a 50 day moving average of $26.18 and a 200 day moving average of $25.46. The firm has a market cap of $455.70 million, a PE ratio of -1.64 and a beta of 1.05. Claritev has a twelve month low of $11.50 and a twelve month high of $55.50.
Claritev (NYSE:CTEV – Get Free Report) last released its earnings results on Monday, November 9th. The company reported $1.77 EPS for the quarter, topping the consensus estimate of ($3.68) by $5.45. The company had revenue of $268.31 million during the quarter. On average, research analysts expect that Claritev will post -15.02 earnings per share for the current fiscal year.
Institutional Trading of Claritev
Several institutional investors have recently made changes to their positions in the business. Entropy Technologies LP purchased a new stake in shares of Claritev during the third quarter worth approximately $265,000. Marshall Wace LLP raised its position in shares of Claritev by 1,569.2% in the third quarter. Marshall Wace LLP now owns 225,890 shares of the company’s stock valued at $4,782,000 after buying an additional 212,357 shares during the last quarter. Engineers Gate Manager LP purchased a new position in shares of Claritev in the second quarter worth about $245,000. Integrated Wealth Concepts LLC purchased a new position in shares of Claritev in the second quarter worth about $44,000. Finally, Public Investment Fund purchased a new stake in Claritev during the 2nd quarter valued at about $43,703,438. Hedge funds and other institutional investors own 87.15% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the stock. Citigroup reissued a “buy” rating and set a $45.00 price objective (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Wells Fargo & Company raised their target price on Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Zacks Research raised shares of Claritev from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research report on Monday, September 21st. Finally, Canaccord Genuity Group lifted their target price on Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Claritev presently has an average rating of “Moderate Buy” and an average target price of $44.83.
Check Out Our Latest Stock Analysis on CTEV
About Claritev
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Recommended Stories
- Five stocks we like better than Claritev
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
